In a pre-COVID-19 world, this week would have seen evidence-based medicine experts gather in Toronto for EBM Live 2020. However, like many other meetings during the pandemic, it has been postponed. Here, I reflect on last year’s meeting and pharma’s journey in improving the reporting of clinical trials.
Resolving conflicts of interest in medicine
At a workshop on managing conflicts of interest in medicine, Chris Winchester, CEO of Oxford PharmaGenesis and co-founder of Open Pharma, argued for openness.